These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9515805)

  • 21. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
    Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy.
    Weyel D; Sedlacek HH; Müller R; Brüsselbach S
    Gene Ther; 2000 Feb; 7(3):224-31. PubMed ID: 10694799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrphostin 4-nitrobenzylidene malononitrile reduces chemotherapy toxicity without impairing efficacy.
    Novogrodsky A; Weisspapir M; Patya M; Meshorer A; Vanichkin A
    Cancer Res; 1998 Jun; 58(11):2397-403. PubMed ID: 9622080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo.
    DeFeo-Jones D; Garsky VM; Wong BK; Feng DM; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Wai J; Senderak ET; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Freidinger R; Huff J; Oliff A; Jones RE
    Nat Med; 2000 Nov; 6(11):1248-52. PubMed ID: 11062536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacokinetics of cyclophosphamide, adriamycin and adriamycin prodrug (HMR 1928) using an ex vivo isolated perfused human lung model (IHLP)].
    Mürdter TE; Linder A; Friedel G; McClellan M; Bohnenstengel F; Sperker B; Kroemer HK; Toomes H; Freitag L; Fritz P
    Pneumologie; 2000 Nov; 54(11):494-8. PubMed ID: 11132546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
    Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
    Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.
    Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Berjeaud JM; Guilhot F; Papot S
    J Med Chem; 2012 May; 55(9):4516-20. PubMed ID: 22515366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy for sarcoma utilizing adenoviral transfer of the beta-glucuronidase and bax genes and an anthracyline prodrug.
    Miller SD; Mohiuddin I; Cao XX; Ozvaran MK; Daniel JC; Roy Smythe W
    J Surg Res; 2004 Oct; 121(2):153-8. PubMed ID: 15501454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57BI/6 mice.
    Dasnois L; Lebtahi K; Abarca-Quinones J; Havaux N; Dupont S; Dubois V; Trouet A
    J Exp Ther Oncol; 2004 Jul; 4(2):167-9. PubMed ID: 15500012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
    Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
    Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity.
    Guillemard V; Uri Saragovi H
    Oncogene; 2004 Apr; 23(20):3613-21. PubMed ID: 15034547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy.
    Friedlos F; Lehouritis P; Ogilvie L; Hedley D; Davies L; Bermudes D; King I; Martin J; Marais R; Springer CJ
    Clin Cancer Res; 2008 Jul; 14(13):4259-66. PubMed ID: 18594008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
    Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
    Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
    Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
    Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.
    Wu W; Luo Y; Sun C; Liu Y; Kuo P; Varga J; Xiang R; Reisfeld R; Janda KD; Edgington TS; Liu C
    Cancer Res; 2006 Jan; 66(2):970-80. PubMed ID: 16424032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin.
    Platel D; Bonoron-Adèle S; Dix RK; Robert J
    Br J Cancer; 1999 Sep; 81(1):24-7. PubMed ID: 10487608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.